{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:35:27Z","timestamp":1747208127462,"version":"3.40.5"},"reference-count":85,"publisher":"Informa UK Limited","issue":"23","funder":[{"name":"AstraZeneca"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.2217\/fon-2020-0156","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T19:44:22Z","timestamp":1589571862000},"page":"1691-1705","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Combination Treatments with Immunotherapy in Brain Metastases Patients"],"prefix":"10.1080","volume":"16","author":[{"given":"Clemence","family":"Henon","sequence":"first","affiliation":[{"name":"Department of Medical Oncology,Gustave Roussy Cancer Campus, Institut d'Oncologie Thoracique (IOT), Gustave Roussy,\rVillejuif,\rFrance"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Remon","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology,Centro Integral Oncol\u00f3gico Clara Campal (HM CIOCC), Hospital HM Delfos, HM Hospitales,\rBarcelona,\rSpain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3521-2535","authenticated-orcid":false,"given":"Lizza EL","family":"Hendriks","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases,GROW - School for Oncology & Developmental Biology, Maastricht University Medical Center+,\rMaastricht,\rThe Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,5,15]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e3181f9456a"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00141-2"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-011-0203-y"},{"key":"e_1_3_2_6_1","volume-title":"Neurologic Complications of Cancer.","author":"DeAngelis LM","unstructured":"DeAngelis LM , PosnerJB. Neurologic Complications of Cancer.2nd Edition. Oxford University Press, Oxford, NY, USA","edition":"2"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-015-0028-8"},{"key":"e_1_3_2_8_1","first-page":"17","article-title":"Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis","volume":"74","author":"Leone JP","year":"2017","unstructured":"Leone JP , LeoneJ, ZwengerAO, IturbeJ, LeoneBA, VallejoCT. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis. Eur. J. Cancer Oxf. Engl. 1990.74, 17\u201325 (2017).","journal-title":"Eur. J. Cancer Oxf. Engl. 1990."},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0790"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2015-000024"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0055-y"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2017.12.007"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.03.009"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy275"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz411"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz056"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz260.005"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz260.004"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.05.015"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30428-X"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302369"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4570"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.7_suppl.546"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3265"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(94)90218-6"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw289"},{"issue":"3","key":"e_1_3_2_33_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00376","article-title":"Tumor mutational burden is site specific in non\u2013small-cell lung cancer and is highest in lung adenocarcinoma brain metastases","author":"Stein MK","year":"2019","unstructured":"Stein MK , PandeyM, XiuJet al. Tumor mutational burden is site specific in non\u2013small-cell lung cancer and is highest in lung adenocarcinoma brain metastases. JCO Precis. Oncol. (3), 1\u201313 (2019).","journal-title":"JCO Precis. Oncol."},{"key":"e_1_3_2_34_1","doi-asserted-by":"crossref","first-page":"v148","DOI":"10.1093\/annonc\/mdz243.013","article-title":"403PD \u2013 Tumour mutational burden and immune infiltrates in primary renal cell carcinoma and matched brain metastases","volume":"30","author":"Steindl A","year":"2019","unstructured":"Steindl A , BergenES, AlparDet al. 403PD \u2013 Tumour mutational burden and immune infiltrates in primary renal cell carcinoma and matched brain metastases. Ann. Oncol.30, v148 (2019).","journal-title":"Ann. Oncol."},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-20622-8"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz207"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.009"},{"issue":"2","key":"e_1_3_2_38_1","first-page":"33","article-title":"The role of the immune system in brain metastasis","volume":"10","author":"Leibold AT","year":"2019","unstructured":"Leibold AT , MonacoGN, DeyM. The role of the immune system in brain metastasis. Curr. Neurobiol.10(2), 33\u201348 (2019).","journal-title":"Curr. Neurobiol."},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2013.03.010"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22110"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1153208"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3073"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2018.03.053"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70324-8"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu577"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805453"},{"key":"e_1_3_2_47_1","article-title":"Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204)","author":"Tawbi H","unstructured":"Tawbi H , ForsythP, HodiFet al. Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204). J. Clin. Oncol. (2019) https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2019.37.15_suppl.9501","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4517"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30111-X"},{"issue":"7","key":"e_1_3_2_50_1","first-page":"1244","article-title":"Outcome of non-small-cell lung cancer patients with brain metastases treated with checkpoint inhibitors","volume":"14","author":"Hendriks LEL","year":"2019","unstructured":"Hendriks LEL , HenonC, AuclinEet al. Outcome of non-small-cell lung cancer patients with brain metastases treated with checkpoint inhibitors. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer14(7), 1244\u20131254 (2019).","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.315"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70090-6"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30053-5"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00204"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02218"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665"},{"issue":"7","key":"e_1_3_2_57_1","first-page":"452","article-title":"Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): final analysis from the NIVOREN GETUG AFU 26 study","volume":"37","author":"Albiges L","year":"2019","unstructured":"Albiges L , NegrierS, DalbanCet al. Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): final analysis from the NIVOREN GETUG AFU 26 study. J.Clin. Oncol.37(Suppl. 7), 452 (2019).","journal-title":"J.Clin. Oncol."},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-2-3"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801946"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.08.424"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30139-6"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.08.053"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30413-9"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0064"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy483"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00990"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0160"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.2521"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.9032"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00244"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1914-6"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2018.08.025"},{"key":"e_1_3_2_73_1","article-title":"Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future directions","volume":"9","author":"Wang Y","year":"2018","unstructured":"Wang Y , DengW, LiNet al. Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future directions. Front. Pharmacol.9, (2018).","journal-title":"Front. Pharmacol."},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00336"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2082"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30723-8"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816047"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00453"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS9603"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0338-6"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30693-9"},{"issue":"10","key":"e_1_3_2_84_1","first-page":"e100","article-title":"Central nervous system pseudoprogression in a patient treated with PD-1 checkpoint inhibitor","volume":"10","author":"Doherty MK","year":"2015","unstructured":"Doherty MK , JaoK, ShepherdFA, HazratiL-N, LeighlNB. Central nervous system pseudoprogression in a patient treated with PD-1 checkpoint inhibitor. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer.10(10), e100\u2013101 (2015).","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer."},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00088-1"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2020.1705788"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw558"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2020-0156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:46:23Z","timestamp":1719125183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2020-0156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,15]]},"references-count":85,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.2217\/fon-2020-0156"],"URL":"https:\/\/doi.org\/10.2217\/fon-2020-0156","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"type":"print","value":"1479-6694"},{"type":"electronic","value":"1744-8301"}],"subject":[],"published":{"date-parts":[[2020,5,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-02-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}